FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Clinical trials for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) explained in plain language.
Never miss a new study
Get alerted when new FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) trials appear
Sign up with your email to follow new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug trial aims to slow muscle loss in rare genetic disease
Disease control TerminatedThis study tested whether an oral drug called losmapimod could slow the progression of muscle weakness in adults with facioscapulohumeral muscular dystrophy (FSHD). For 48 weeks, 260 participants took either the drug or a placebo pill twice daily. The main goal was to see if the …
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Phase: PHASE3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Extended drug trial seeks to tame debilitating muscle disease
Disease control TerminatedThis study aimed to check the long-term safety of a drug called losmapimod for adults with facioscapulohumeral muscular dystrophy (FSHD), a condition that weakens muscles. It was an extension of a previous trial, allowing participants to continue taking the drug. The main goal wa…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC